Skip to content

R&D at other companies

Teladoc Health logo
Teladoc HealthTDOC
$67.87M-3.0%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$150.15M+263%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$46.04M-8.3%
Insulet logo
InsuletPODD
$89.7M+50.5%
Eli Lilly logo
Eli LillyLLY
$3.51B+28.4%
Hinge Health, Inc. logo
Hinge Health, Inc.HNGE
$30.34M+29.1%

Other financials

Income statement

See full
Revenue$78.0M+42.0%
Gross profit$48.7M+52.6%
Operating income-$4.8M+43.1%
Net income-$3.0M+68.6%
EPS (diluted)-$0.05+95.7%

Balance sheet

See full
Cash & equivalents$211.8M+257%
Total debt$30.0M
Total equity$234.1M+160%
Total assets$302.8M

Cash flow

See full
Operating cash flow-$11.8M+26.6%
CapEx$78.0K-75.2%
Free cash flow-$11.9M+27.5%

Valuation

See full
Market cap$1.11B+23.8%
P/S3.9×-0.4×

Profitability

See full
Gross margin66.3%+4.4pp
Operating margin-9.6%-4.0pp
Net margin-11.3%-4.6pp
FCF margin-40.8%

Returns & leverage

See full
Return on equity26.8%
Debt / equity0.1×
Current ratio3.9×

Where this comes from

Reported directly by OMDA in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: OMDA’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about OMDA's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OMDA's R&D?
OMDA (OMDA) reported R&D of $12.7M in Q1 2026.
How has OMDA's R&D changed year-over-year?
OMDA's R&D increased by 44.2% year-over-year, from $8.81M to $12.7M.
What is the long-term trend for OMDA's R&D?
Over 2 years (2023 to 2025), OMDA's R&D has grown at a 9.8% compound annual growth rate (CAGR), from $33.74M to $40.68M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.